IRDye 800CW RGD Optical Probe is a BrightSite™ near-infrared (NIR) fluorescently-labeled RGD imaging agent specifically designed to target the overexpression of integrins on tumors.

Integrins are cell surface heterodimeric glycoproteins involved in cell-to-cell and cell-to-matrix interactions. IRDye 800CW RGD Optical Probe is composed of the recognition motif, RGD (Arg-Gly-Asp), a tripeptide sequence used to bind integrin receptors including α_vβ₃. This receptor class is involved in tumor growth, tumor invasiveness, metastasis, tumor induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis.

Interest in using a labeled RGD peptide ligand for the study and/or monitoring of diseases related to the α_vβ₃ receptor over-expression is increasing. Several groups have labeled RGD successfully with fluorescent dyes for in vitro and in vivo imaging.

Learn about other LI-COR optical probes.

Applications

• Microscopy
• Optical Probe Development
• Target Specificity

Absorbance and Emission Spectra

Data Example

Reference

1. Huang, R., Vider, J., Kovar, J. L., Olive, D. M., Mellinghoff, I. K., Mayer-Kuckuk, P., … Blasberg, R. G. (2012). Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical Cancer Research, 18(20), 5731–5740. doi: 10.1158/1078-0432.CCR-12-0374.